Clinical study of VERU-111, an oral cytoskeletal disruptor in men with metastatic Castration Resistant Prostate Cancer (mCRPC) who failed an androgen receptor targeting agent

Authors :: Emmanuel S. Antonarakis
Robert H. Getzenberg
Ronald F. Tutrone
Daniel Saltzstein
D. Rodriguez
K.G. Barnette
Mario A. Eisenberger
Mitchell S. Steiner
Christopher Michael Pieczonka
Mark C. Markowski
Source :: European Urology. 79:S1202
Publication Year :: 2021
Publisher :: Elsevier BV, 2021.

Subjects :: Androgen receptor
Clinical study
Prostate cancer
business.industry
Urology
Cancer research
Medicine
Castration resistant
business
Cytoskeleton
medicine.disease

Full Text Access

Tools